These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3278428)

  • 1. Reexposure to OKT3 in renal allograft recipients.
    Mayes JT; Thistlethwaite JR; Stuart JK; Buckingham MR; Stuart FP
    Transplantation; 1988 Feb; 45(2):349-53. PubMed ID: 3278428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reuse of OKT3 after previous rejection or induction therapy in cadaveric renal transplantation.
    Shield CF; Hughes JD
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):35-8. PubMed ID: 2510509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preventive treatment of rejection by the prolonged administration of OKT3: decrease of the immune response of the host].
    Debure A; Chkoff N; Chatenoud L; Lacombe M; Campos H; Noël LH; Goldstein G; Bach JF; Kreis H
    Nephrologie; 1987; 8(3):87-94. PubMed ID: 3116443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring immunosuppression following renal transplantation.
    Giorgi JV; Cosimi AB; Colvin RB; Goldstein G; Delmonico FL; Russell PS
    Diagn Immunol; 1983; 1(3):174-8. PubMed ID: 6388969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful retreatment of allograft rejection with OKT3.
    First MR; Schroeder TJ; Hurtubise PE; Mansour ME; Penn I; Munda R; Balistreri WF; Alexander JW; Melvin DB; Fidler JP
    Transplantation; 1989 Jan; 47(1):88-91. PubMed ID: 2521410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence of antibody formation to OKT3 consequent to its use in organ transplantation.
    Carey G; Lisi PJ; Schroeder TJ
    Transplantation; 1995 Jul; 60(2):151-8. PubMed ID: 7624957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic use of OKT3 monoclonal antibody for acute renal allograft rejection.
    Norman DJ; Shield CF; Barry JM; Henell K; Funnell MB; Lemon J
    Nephron; 1987; 46 Suppl 1():41-7. PubMed ID: 3306424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with OKT3 and cyclosporine for acute allograft rejection.
    Schulak JA; Mayes JT; Hricik DE
    Transplant Proc; 1991 Aug; 23(4):2119-22. PubMed ID: 1908150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts].
    Chatenoud L; Bach JF
    Nephrologie; 1987; 8(3):95-8. PubMed ID: 3309702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3.
    Chatenoud L; Baudrihaye MF; Chkoff N; Kreis H; Goldstein G; Bach JF
    J Immunol; 1986 Aug; 137(3):830-8. PubMed ID: 3487589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.
    Bock HA; Gallati H; Zürcher RM; Bachofen M; Mihatsch MJ; Landmann J; Thiel G
    Transplantation; 1995 Mar; 59(6):830-40. PubMed ID: 7701577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection.
    Norman DJ; Shield CF; Barry J; Bennett WM; Henell K; Kimball J; Funnell B; Hubert B
    Am J Kidney Dis; 1988 Feb; 11(2):107-10. PubMed ID: 3277400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications and monitoring of OKT3 therapy.
    Thistlethwaite JR; Stuart JK; Mayes JT; Gaber AO; Woodle S; Buckingham MR; Stuart FP
    Am J Kidney Dis; 1988 Feb; 11(2):112-9. PubMed ID: 3277401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients.
    Toyoda M; Galfayan K; Wachs K; Czer L; Jordan SC
    Clin Transplant; 1995 Dec; 9(6):472-80. PubMed ID: 8645891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody OKT3 therapy in pediatric kidney transplant recipients.
    Leone MR; Barry JM; Alexander SR; Melvin T; Striegel J; Reller K; Henell KR; Kimball J; Funnell MB; Goldstein G
    J Pediatr; 1990 May; 116(5):S86-91. PubMed ID: 2139465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients.
    Waid TH; Lucas BA; Thompson JS; Brown SA; Munch L; Prebeck RJ; Jezek D
    Transplantation; 1992 Jan; 53(1):80-6. PubMed ID: 1531095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent.
    Vigeral P; Chkoff N; Chatenoud L; Campos H; Lacombe M; Droz D; Goldstein G; Bach JF; Kreis H
    Transplantation; 1986 Jun; 41(6):730-3. PubMed ID: 3520988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies to human T cell subsets: use for immunological monitoring and immunosuppression in renal transplantation.
    Burton RC; Cosimi AB; Colvin RB; Rubin RH; Delmonico FL; Goldstein G; Russell PS
    J Clin Immunol; 1982 Jul; 2(3 Suppl):142S-147S. PubMed ID: 6290526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.